| abstract |
The present invention provides a binding composition associated with a chemotherapeutic agent, eg, a combination comprising an anti-IGFR1 antibody. Also provided is the use of the same combination to treat medical conditions such as cancer. The invention is defined by (a) one or more binding compositions, such as any anti-IGFR1 antibody, preferably an isolated fully human monoclonal antibody, preferably (i) SEQ ID NO: 5. A light chain amino acid sequence comprising CDR-L1, defined by SEQ ID NO: 6, and CDR-L3 defined by SEQ ID NO: 7, and (ii) CDR-H1, defined by SEQ ID NO: 8, An antibody selected from the group consisting of a heavy chain amino acid sequence comprising CDR-H2 defined by SEQ ID NO: 9 and CDR-H3 defined by SEQ ID NO: 10, (b) one or more chemotherapeutic agents; And, optionally, a composition comprising optionally combined with a pharmaceutically acceptable carrier. |